AstraZeneca Tries Plan B For Dato-DXd After Regulator Feedback

 
• By Andrew McConaghie

The FDA said the antibody-drug conjugate looks more promising in a subgroup of EGFR mutated lung cancer patients, which caused AstraZeneca to refile the application.

AZ is looking for a narrower indication for its lung cancer candidate after withdrawing its initial FDA application. (Shutterstock)

More from Review Pathways

More from Pathways & Standards